BioChaperone AsPram

BioChaperone AsPram is an **investigational bi-hormonal peptide combination therapy** from **Adocia** for diabetes, formulated with the company's BioChaperone technology to co-formulate **insulin aspart** and **pramlintide** together at physiologic pH. The therapeutic concept is to more closely reproduce the physiologic co-secretion of insulin and amylin by delivering a rapid-acting prandial insulin analog alongside an amylin analog in a single formulation. Insulin aspart lowers glucose primarily through activation of the insulin receptor, while pramlintide acts as an amylin receptor agonist to slow gastric emptying, suppress inappropriate postprandial glucagon secretion, and promote satiety, with the goal of improving postprandial glycemic control in **type 1 diabetes** and **type 2 diabetes**. Based on the provided information, BioChaperone AsPram remained in the **preclinical** stage and had not yet entered clinical trials.

Other names

insulin aspart + pramlintide